더바이오 11월 5일 주요뉴스 [https://www.thebionews.net/edit/webzine.html?idxno=677](https://www.thebionews.net/edit/webzine.html?idxno=677) ● 제약바이오 3Q 실적 희비…고수익 제품·신사업 성과로 셀트리온·대웅 ‘약진’ [https://www.thebionews.net/news/articleView.html?idxno=29863](https://www.thebionews.net/news/articleView.html?idxno=29863) ● [분석] BMS, 오름과 ‘ORM-6151’ 계약 종료 왜?…후속 ‘ORM-1153’의 차별성은 [https://www.thebionews.net/news/articleView.html?idxno=29897](https://www.thebionews.net/news/articleView.html?idxno=29897) ● [컨콜] 노보 ‘위고비필’ 3Q 매출 1조원 돌파…‘카그리세마’ 내년 美 출시 추진 [https://www.thebionews.net/news/articleView.html?idxno=29867](https://www.thebionews.net/news/articleView.html?idxno=29867) ● 베링거, 中 시노와 ADC·T세포 TCE 항암 후보 9.7조원 규모 라이선스 딜 [https://www.thebionews.net/news/articleView.html?idxno=29865](https://www.thebionews.net/news/articleView.html?idxno=29865) ● “넥스트 반도체는 바이오”…국가 자문기구 3곳, ‘바이오 대혁신’에 한 목소리 [https://www.thebionews.net/news/articleView.html?idxno=29910](https://www.thebionews.net/news/articleView.html?idxno=29910) ● 뉴릭스 “사노피, ‘STAT6 분해제’ 1상 중단”…최대 6100억원 후속 기술료 무산 [https://www.thebionews.net/news/articleView.html?idxno=29896](https://www.thebionews.net/news/articleView.html?idxno=29896) ● 지아이, GI-102·J&J 차세대 T세포 인게이저 병용 글로벌 임상 첫 환자 투약 [https://www.thebionews.net/news/articleView.html?idxno=29885](https://www.thebionews.net/news/articleView.html?idxno=29885) ● ‘K바이오’, 제2의 반도체 신화 도전…투자 확대·규제 혁신 모색 [https://www.thebionews.net/news/articleView.html?idxno=29888](https://www.thebionews.net/news/articleView.html?idxno=29888) ● 오스코텍, 밸류업 이행 현황 공개…기술이전·흑자전환 목표 조기 달성 [https://www.thebionews.net/news/articleView.html?idxno=29911](https://www.thebionews.net/news/articleView.html?idxno=29911) ● 동아에스티, 디앤티홀딩컴퍼니 지분 약 399억원 규모 전량 매각 [https://www.thebionews.net/news/articleView.html?idxno=29912](https://www.thebionews.net/news/articleView.html?idxno=29912) ● ‘“10초 투여’로 심장 진단 편의성↑”…GE헬스케어, ‘라피스캔’ 국내 상륙 [https://www.thebionews.net/news/articleView.html?idxno=29898](https://www.thebionews.net/news/articleView.html?idxno=29898) ● SK바이오팜, 3분기 영업익 1000억원 넘겼다…누적 3000억원 돌파(종합) [https://www.thebionews.net/news/articleView.html?idxno=29895](https://www.thebionews.net/news/articleView.html?idxno=29895) ● SK바이오사이언스, 3Q 매출 전년比 21%↑…세전이익 흑자전환 [https://www.thebionews.net/news/articleView.html?idxno=29918](https://www.thebionews.net/news/articleView.html?idxno=29918) ● 큐로셀, ASH서 '림카토' 장기 추적 결과 공개…장기반응군 3년 생존율 81.6% [https://www.thebionews.net/news/articleView.html?idxno=29879](https://www.thebionews.net/news/articleView.html?idxno=29879) ● 디앤디파마텍 ‘바이오 유럽 2026’ 참가…글로벌 파트너링 논의 [https://www.thebionews.net/news/articleView.html?idxno=29905](https://www.thebionews.net/news/articleView.html?idxno=29905) ● 지투지바이오, 美 PODD 이어 ‘바이오유럽’ 참가…글로벌 기술사업화 속도 [https://www.thebionews.net/news/articleView.html?idxno=29883](https://www.thebionews.net/news/articleView.html?idxno=29883) ● 신라젠, ‘BAL0891’ 美 1상 변경 신청…요로상피암 병용요법 평가 [https://www.thebionews.net/news/articleView.html?idxno=29916](https://www.thebionews.net/news/articleView.html?idxno=29916) ● HLB이노 美 자회사 베리스모, CAR-T 임상1상서 반응률 80%·완전관해 60% [https://www.thebionews.net/news/articleView.html?idxno=29880](https://www.thebionews.net/news/articleView.html?idxno=29880) ● 바이오엔테크, 3Q 매출 감소에도 흑자 전환…이중항체·ADC 개발 확대 [https://www.thebionews.net/news/articleView.html?idxno=29848](https://www.thebionews.net/news/articleView.html?idxno=29848) ● ABL Bio pursues global collaboration for BBB shuttle and 4-1BB bispecific antibodies at BIO Europe [https://www.thebionews.net/news/articleView.html?idxno=29919](https://www.thebionews.net/news/articleView.html?idxno=29919) ● Y-Biologics expands global business development built on ‘Multi-AbKine’ at BIO Europe [https://www.thebionews.net/news/articleView.html?idxno=29915](https://www.thebionews.net/news/articleView.html?idxno=29915) ● HLB Innovation's U.S. subsidiary Verismo reports 80% response rate and 60% complete remission in Phase 1 CAR-T clinical trial [https://www.thebionews.net/news/articleView.html?idxno=29909](https://www.thebionews.net/news/articleView.html?idxno=29909) ● Curocell reveals 3-year long-term follow-up results of 'RIMQARTO' at ASH, with long-term responder group posting 81.6% 3-year survival rate [https://www.thebionews.net/news/articleView.html?idxno=29908](https://www.thebionews.net/news/articleView.html?idxno=29908) ● G2GBIO joins ‘BIO Europe’ after U.S. PODD, speeding up global technology commercialization [https://www.thebionews.net/news/articleView.html?idxno=29907](https://www.thebionews.net/news/articleView.html?idxno=29907) ● D&D Pharmatech heads into Phase 1 trials for liver fibrosis drug candidate in 2027 – “Oral peptide development expanding” [https://www.thebionews.net/news/articleView.html?idxno=29906](https://www.thebionews.net/news/articleView.html?idxno=29906) ● Samsung Bioepis signs U.S. marketing rights deal with Teva for two biosimilar autoimmune disease treatments [https://www.thebionews.net/news/articleView.html?idxno=29891](https://www.thebionews.net/news/articleView.html?idxno=29891) ● GI Innovation Initiates Global Clinical Trial of GI-102 in Combination with Next-Generation T cell engager, Dosing First Patient [https://www.thebionews.net/news/articleView.html?idxno=29890](https://www.thebionews.net/news/articleView.html?idxno=29890) ● Celltrion reveals preclinical results for world's first 'quadruple-action obesity treatment' candidate [https://www.thebionews.net/news/articleView.html?idxno=29884](https://www.thebionews.net/news/articleView.html?idxno=29884) ● HLB, Elevar's liver cancer drug candidate enters FDA 'full review,' with April 2027 set as target review date [https://www.thebionews.net/news/articleView.html?idxno=29864](https://www.thebionews.net/news/articleView.html?idxno=29864) *제약바이오 11월 5일 아침 유튜브 라디오 뉴스(매일 아침 업로드) [https://www.youtube.com/watch?v=Jv8wfMwQJAM](https://www.youtube.com/watch?v=Jv8wfMwQJAM)